Optimi Health (OPTI) Registration filing summary

Company overview and business model

• Canadian GMP-compliant pharmaceutical manufacturer specializing in MDMA and psilocybin from botanical sources, licensed by Health Canada for controlled substances.

• Vertically integrated with two 10,000 sq. ft. production facilities in Princeton, BC, operating under a Drug Establishment Licence (DEL) and Dealer's Licence (DL).

• Products are available in Australia (prescription for TRD and PTSD), Canada (Special Access Program), and for clinical trials in Israel; U.S. market entry is pending regulatory changes.

• Focus on sustainable, responsible production, advanced extraction technologies, and proprietary know-how rather than patents.

• Winding down nutraceutical business to focus on pharmaceutical-grade manufacturing.

Financial performance and metrics

• Fiscal year ended September 30, 2025: revenue C$426,301 (US$306,097), net loss C$3,712,031 (US$2,665,349), accumulated deficit C$27,241,680 (US$20,001,233).

• Three months ended December 31, 2025: revenue C$232,700, net loss C$1,553,975 (US$1,133,296).

• Cash and cash equivalents as of December 31, 2025: C$491,750.

• Ongoing operating losses, negative cash flow from operations, and reliance on equity and debt financing.

Use of proceeds and capital allocation

• Net proceeds from IPO (estimated US$13.7 million at US$7.00/share) allocated as: 25.5% for scaling production/distribution, 16% for market entry to Israel and U.S., 58.5% for working capital and operating expenses.

• Funds expected to support scaling and market expansion for 12 months; additional capital will be needed for U.S. entry beyond that period.